Atrial Fibrillation News and Research RSS Feed - Atrial Fibrillation News and Research

Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen, Bayer HealthCare initiate CALLISTO program to study rivaroxaban in patients with active cancer

Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new comprehensive clinical research program for their novel oral anticoagulant, rivaroxaban, in patients with active cancer. The studies are evaluating the medicine for the prevention and treatment of life-threatening blood clots in patients with a wide range of cancer types. [More]
COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

COPD associated with increased mortality in patients with atrial fibrillation, but not stroke

Chronic obstructive pulmonary disease, or COPD, is associated with increased risk of dying from a cardiovascular disease such as heart failure or a heart attack, as well as diseases not associated with the heart. However, COPD is not by itself associated with increased likelihood of having a stroke or a systemic embolism, according to a new research study. [More]
Researchers use American College of Cardiology registry to improve cardiovascular care delivery in India

Researchers use American College of Cardiology registry to improve cardiovascular care delivery in India

Despite challenges, it is feasible to collect and study the quality of outpatient cardiovascular care in a resource-limited environment like India, according to a pilot study published today in the Journal of the American Heart Association. [More]
Cardiology researchers uncover new evidence that relates to increased risk of stroke

Cardiology researchers uncover new evidence that relates to increased risk of stroke

Cardiology researchers at The Queen Elizabeth Hospital have uncovered new evidence that relates to patients with new onset atrial fibrillation (AF) and their increased risk of stroke. [More]
Post-operative atrial fibrillation can significantly increase risk of heart attack or stroke

Post-operative atrial fibrillation can significantly increase risk of heart attack or stroke

As many as 12 percent of patients undergoing major, non-cardiac surgery experience an irregular heartbeat called atrial fibrillation. [More]
No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

No data exists to support long-term efficacy, safety of e-cigarettes as smoking cessation tool

There is little reliable evidence that electronic cigarettes are effective for long-term smoking cessation, according to a new analysis of the currently available research which was presented at the 2015 American Thoracic Society International Conference. [More]
Cardiome signs commercialization agreement with AOP for ESMOCARD products

Cardiome signs commercialization agreement with AOP for ESMOCARD products

Cardiome Pharma Corp. today announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD and ESMOCARD LYO (esmolol hydrochloride) in Italy, France, Spain and Belgium. [More]
RIT's Behnaz Ghoraani awarded NIH grant to develop new atrial fibrillation solution

RIT's Behnaz Ghoraani awarded NIH grant to develop new atrial fibrillation solution

Behnaz Ghoraani, engineering faculty at Rochester Institute of Technology, was recently awarded a $456,000 grant from the National Institutes for Health for the project "Catheter guidance algorithm for identification of atrial fibrillation ablation." [More]
Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Boston Scientific signs two strategic agreements to bring comprehensive solutions to healthcare systems

Boston Scientific announces the signing of two strategic agreements to advance the company's efforts to bring value based solutions aimed at improving outcomes and reducing the cost of cardiovascular care delivery to healthcare systems. [More]
Atrial fibrillation linked to only one type of heart attack

Atrial fibrillation linked to only one type of heart attack

Refining the results of a 2013 study, researchers have found that atrial fibrillation, or irregular heartbeat, is associated with only one type of heart attack - the more common of the two types. [More]
Specific altered function in heart's left atrium may signal stroke risk in people with a-fib

Specific altered function in heart's left atrium may signal stroke risk in people with a-fib

Stroke is a frequent and dreaded complication of atrial fibrillation. But predicting which of the estimated six million Americans with a-fib are at highest risk has long challenged physicians weighing stroke risk against the serious side effects posed by lifelong therapy with warfarin and other blood thinners. [More]
Record number of abstracts submitted to Heart Failure 2015

Record number of abstracts submitted to Heart Failure 2015

A record number of abstracts have been submitted to the world's leading heart failure congress, promising more original science than ever before. [More]
Study shows NASH linked to 50% higher death rates compared with NAFLD

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD). [More]
Two Louisville heart physicians to host symposium on cardiovascular disease in women

Two Louisville heart physicians to host symposium on cardiovascular disease in women

Two of Louisville's leading heart physicians will host a one-day symposium designed to provide the community, physicians, nurses and health professionals up-to-date information on the prevention, diagnosis and treatment of cardiovascular disease in women. [More]
CPAP use reduces atrial fibrillation recurrence in patients with obstructive sleep apnea

CPAP use reduces atrial fibrillation recurrence in patients with obstructive sleep apnea

The use of continuous positive airway pressure was associated with a significant reduction in the recurrence of atrial fibrillation in patients with obstructive sleep apnea, according to an analysis of data from past research published today in the Journal of the American College of Cardiology: Clinical Electrophysiology. [More]
Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) data presented yesterday by Pharmacyclics, Inc. at the American Association for Cancer Research Annual Meeting suggest that ibrutinib may be an effective therapeutic option for pancreatic ductal adenocarcinoma (PDAC), as shown in both a transgenic mouse model and an in-vivo model of patient-derived xenograft (PDX) mice (grafts of tissue taken from a pancreatic cancer patient and grafted into a mouse). [More]
Study sheds light on the physical causes of sudden death

Study sheds light on the physical causes of sudden death

Sudden cardiac death accounts for approximately 10% of natural deaths, most of which are due to ventricular fibrillation. Each year it causes 300,000 deaths in the United States and 20,000 in Spain. [More]

Study looks at dabigatran adherence across Veterans Health Administration sites

Among patients with atrial fibrillation who filled prescriptions for the anticoagulant dabigatran at Veterans Health Administration sites, there was variability in patient medication adherence across sites, with appropriate patient selection and pharmacist-led monitoring associated with greater adherence to the medication, according to a study in the April 14 issue of JAMA. [More]
Newly approved drug for rare blood cancer shows sustained benefit for 2 years

Newly approved drug for rare blood cancer shows sustained benefit for 2 years

The most recent results from a clinical trial show that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continued to control the rare blood cancer, with 95 percent of patients surviving for two years, report investigators from Dana-Farber Cancer Institute. [More]
Cardiome Pharma receives reimbursement status for BRINAVESS in Belgium

Cardiome Pharma receives reimbursement status for BRINAVESS in Belgium

Cardiome Pharma Corp. today announced the approval of BRINAVESS for reimbursement by Belgium's national compulsory health care and benefits insurance authority, The National Institute for Health and Disability Insurance (Institut National d'Assurance Maladie Invalidité or INAMI). As a result of this decision, BRINAVESS is expected to be listed for reimbursement in Belgium as of June 1, 2015. [More]
Advertisement
Advertisement